Compare Global X Defense Tech ETF (SHLD) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global X Defense Tech ETF vs State Street SPDR S&P Biotech ETF — how do they compare? Global X Defense Tech ETF trades at $59.87 (market cap $6.29B), while State Street SPDR S&P Biotech ETF trades at $153.75 (market cap $10.11B). The key difference: State Street SPDR S&P Biotech ETF is the larger of the two by market cap, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Global X Defense Tech ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Global X Defense Tech ETF for 44 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| SHLD | XBI | |
|---|---|---|
Market Cap | $6.29B | $10.11B |
Volume | 1,133,252 | 12,903,266 |
Sector | Sector/Thematic | Broad Market / Factor |
52-Week High | $78.02 | $169.55 |
52-Week Low | $58.20 | $104.99 |
Typical Hold Time | 44 Days | 38 Days |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SHLD, the Global X Defense Tech ETF, trades at $59.19, up 0.77% today, but technical indicators signal a bearish trend with moving averages and ADX pointing lower, while RSI levels suggest potential oversold conditions. The fund focuses on defense technology and cybersecurity, benefiting from rising global defense budgets, as highlighted by recent institutional buying and positive news flow on European rearmament efforts.
The outlook for SHLD is supported by geopolitical tailwinds and institutional accumulation, but near-term technical weakness and reliance on defense spending cycles pose risks. Investors gain exposure to innovative defense firms, yet must monitor budget approvals and market volatility.
XBI trades at $149.29, down 0.63% on the day, with technical indicators showing a bearish bias despite oversold RSI conditions. The ETF faces mixed sentiment with 100% hold ratings from analysts but positive catalysts from biotech breakthroughs. Recent news highlights XBI's 76% rally over the past year and ongoing M&A activity driving sector optimism.
Outlook remains cautiously optimistic with potential upside from cancer vaccine developments and sector consolidation, though high volatility and expense ratios relative to broader healthcare ETFs present risks. The ETF's modified equal-weight structure offers diversified exposure to 150+ biotech names, benefiting from improved capital access and clinical trial catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Global X Defense Tech ETF
SHLD tracks the Global X Defense Tech Index, targeting companies that lead the technological transformation of the defense sector. It focuses on pure-play innovators in cybersecurity, artificial intelligence, robotics, and advanced military systems, excluding traditional commercial aerospace to maintain a high level of thematic purity.
Read more on SHLD →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
